Impact BioMedical, INC. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Impact BioMedical, INC. (IBO) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$3.03 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-11.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-11
- Impact BioMedical, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$3.03M.
- Impact BioMedical, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$5.24M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$3.03M 10-K · filed 2026-03-11 |
| 2024-12-31 | -$5.24M 10-K · filed 2026-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |